Restoration of β-Globin Expression with Optimally Designed Lentiviral Vector for β-Thalassemia Treatment in Chinese Patients,Human Gene Therapy

当前位置： X-MOL 学术 › Hum. Gene Ther. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Restoration of β-Globin Expression with Optimally Designed Lentiviral Vector for β-Thalassemia Treatment in Chinese Patients
Human Gene Therapy ( IF 4.2 ) Pub Date : 2021-05-17 , DOI: 10.1089/hum.2020.204
Wenjie Ouyang _{1,

2,

3} , Guoyi Dong _{1,

2,

3,

4} , Weihua Zhao ₅ , Jing Li _{1,

2,

3,

4} , Ziheng Zhou _{1,

2} , Gaohui Yang ₆ , Rongrong Liu ₆ , Yue Li ₇ , Qiaoxia Zhang ₅ , Xin Du ₅ , Haixi Sun _{1,

2} , Ying Gu _{1,

2,

3} , Yongrong Lai ₆ , Sixi Liu ₇ , Chao Liu _{1,

2,

3}

Affiliation

β-Thalassemia is one of the most prevalent genetic diseases worldwide. The current treatment for β-thalassemia is allogeneic hematopoietic stem cell transplantation, which is limited due to lack of matched donors. Gene therapy has been developed as an alternative therapeutic option for transfusion-dependent β-thalassemia (TDT). However, successful gene therapy for β-thalassemia patients in China has not been reported. Here, we present the results of preclinical studies of an optimally designed lentiviral vector (LV) named LentiHBB^T87Q in hematopoietic stem and progenitor cells (HSPCs) derived from Chinese TDT patients. LentiHBB^T87Q was selected from a series of LVs with optimized backbone and de novo cloning strategy. It contains an exogenous T87Q β-globin gene (HBB^T87Q) driven by a specific reconstituted locus control region, and efficiently expresses HBB mRNA and HBB protein in erythroblasts derived from cord blood HSPCs. To facilitate clinical transformation, we manufactured clinical-grade LentiHBB^T87Q (cLentiHBB^T87Q) and optimized its transduction procedure. Importantly, transduction of cLentiHBB^T87Q restored expression of HBB monomer and adult hemoglobin tetramer to relatively normal level in erythroblasts from bone marrow HSPCs of Chinese TDT patients that carry the most common mutation types and cover various genotypes, including β0/β0. Furthermore, viral integration sites (VISs) of cLentiHBB^T87Q were similar to other LVs safely used in previous clinical trials, and gene-ontology (term) analysis of VIS targeted genes suggests that no tumor-associated pathways were enriched in treated samples. Taken together, we have engineered the cLentiHBB^T87Q that can restore β-globin expression in the HSPCs-derived erythroblasts of Chinese TDT patients with minimal risk of tumorigenesis, providing a favorable starting point for future clinical application.

更新日期：2021-05-18

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>